布地奈德/福莫特罗干粉吸入剂联合孟鲁司特钠治疗咳嗽变异性哮喘的疗效评价  

Effects of therapy of Budesonide/Formotero inhalation combined with montelukast in the patients with cough variant asthma

作　　者：刘广杰[1] 罗秀芳[1] 

机构地区：[1]首都医科大学附属北京同仁医院呼吸内科,北京100730

出　　处：《中国医药导报》2015年第36期36-39,共4页China Medical Herald

摘　　要：目的 探讨应用孟鲁司特钠联合布地奈德/福莫特罗干粉吸入剂治疗咳嗽变异性哮喘的疗效。方法 总结2012年1月-2014年12月首都医科大学附属北京同仁医院门诊收治的患者40例,分为观察组（孟鲁司特钠联合布地奈德/福莫特罗干粉吸入剂）和对照组（布地奈德/福莫特罗干粉吸入剂）,分析两组咳嗽症状评分、肺功能指标、莱彻斯特咳嗽问卷（LCQ）评分,比较其治疗效果。结果 治疗后两组患者的临床症状均得到明显改善,两组治疗后咳嗽评分、LCQ咳嗽生活质量评分均较治疗前明显改善,差异均有统计学意义（P〈0.01）。观察组咳嗽评分和LCQ咳嗽生活质量评分均较对照组明显改善,差异均有统计学意义（P〈0.05）。两组治疗后肺功能指标观察峰流速%、一秒量占预计值%均较治疗前明显改善,差异均具有统计学意义（P〈0.01）。治疗后观察组峰流速%优于对照组,差异均有统计学意义（P〈0.05）。两组在治疗中均无严重不良反应发生。结论 布地奈德/福莫特罗干粉吸入剂联合口服孟鲁司特钠片剂治疗咳嗽变异性哮喘,能显著提高治疗效果,改善患者生活质量。Objective To explore the therapeutic efficacy of therapy of montelukast combined with Budesonide/For- motero inhalation in patients with cough variant asthma （CVA）. Methods Clinical features of 40 patients with CVA treated in the Affiliated Beijing Tongren Hospital of Capital Medical University from January 2012 to December 2014 were analyzed, including 20 patients treated by Budesonide/Formotero aerosol inhalation combined with montelukast o- ral （observation group） and 20 patients treated by Budesonide/Formotero inhalation only （control group）. Patients＂ cough symptom score （PCSS）, lung function （PEF%, FEV1%） and quality-of-life of the patients with cough by leicester cough questionnaire （LCQ） were eValuated and analyzed between two groups before and after treatment. Results After treat- ment, PCSS in both observation group and control group were significantly decreased than those without treatment （P 〈 0.01）; LCQ scores in both observation group and control group were significantly higher than those without treatment（P 〈 0.01）; The scores of PCSS and LCQ in observation group were significantly improved those in control group （P 〈 0.05）. Both observation group and control group treatment significantly increased lung function index, compared with those without treatment （P 〈 0.01）. After treatment, PEF% in observation group was significantly higher than that in control gToup（p 〈 0.05）. There were no serious adverse reactions in two groups. Conclusion Budesonide/Formotero in- halation combinated with montelukast in the treatment of CVA can effectively improve therapeutic effects and improve patients living condition.

关 键 词：布地奈德/福莫特罗 孟鲁司特钠 咳嗽变异性哮喘 

分 类 号：R969.4[医药卫生—药理学]